Table 2.
Combinations of drug prescription
| Overall (N = 1056) | Tertiary (N = 604) | Secondary (N = 144) | Primary (N = 308) | P value | |
|---|---|---|---|---|---|
| BB (monotherapy) | 60 (5.7%) | 26 (4.3%) | 2 (1.4%) | 32 (10.5%) | <0.001 |
| MRA (monotherapy) | 6 (0.6%) | 5 (0.8%) | 0 (0%) | 1 (0.3%) | 0.40 |
| iRA (monotherapy) | 24 (2.3%) | 5 (0.8%) | 3 (2.1%) | 16 (5.3%) | <0.001 |
| ACE‐I | 10 (1%) | 3 (0.5%) | 2 (1.4%) | 5 (1.6%) | 0.21 |
| ARB | 3 (0.3%) | 1 (0.2%) | 0 (0%) | 2 (0.7%) | 0.33 |
| ARNI | 9 (0.9%) | 1 (0.2%) | 1 (0.7%) | 7 (2.3%) | 0.004 |
| BB + iRA (bitherapy) | 190 (18.2%) | 94 (15.7%) | 29 (20.1%) | 67 (22.1%) | 0.048 |
| BB + ACE‐I | 109 (10.5%) | 58 (9.8%) | 18 (12.5%) | 33 (10.9%) | 0.612 |
| BB + ARB | 34 (3.2%) | 16 (2.7%) | 9 (6.3%) | 9 (3%) | 0.087 |
| BB + ARNI | 34 (3.2%) | 9 (1.5%) | 2 (1.4%) | 23 (7.6%) | <0.001 |
| BB + MRA (bitherapy) | 50 (4.8%) | 28 (4.7%) | 9 (6.3%) | 13 (4.3%) | 0.66 |
| iRA + MRA (bitherapy) | 46 (4.4%) | 20 (3.3%) | 5 (3.5%) | 21 (7%) | 0.035 |
| ACE‐I + MRA | 25 (2.4%) | 15 (2.5%) | 4 (2.8%) | 6 (2%) | 0.841 |
| ARB + MRA | 8 (0.8%) | 2 (0.3%) | 1 (0.7%) | 5 (1.7%) | 0.097 |
| ARNI + MRA | 11 (1.1%) | 2 (0.4%) | 0 (0%) | 9 (3%) | <0.001 |
| BB + iRA + MRA (triple therapy) | 653 (62.7%) | 415 (69.2%) | 95 (66%) | 143 (48%) | <0.001 |
| BB + ACE‐I + MRA | 328 (31.8%) | 226 (38.3%) | 51 (35.4%) | 51 (17.1%) | <0.001 |
| BB + ARB + MRA | 119 (11.4%) | 85 (14.1%) | 13 (9%) | 21 (7%) | 0.004 |
| BB + ARNI + MRA | 179 (17.2%) | 89 (14.8%) | 31 (21.5%) | 59 (20.1%) | 0.047 |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta‐blockers; iRA, renin–angiotensin inhibitors; MRA, mineralocorticoid receptor antagonist.